Nelson R G, Knowler W C, Pettitt D J, Saad M F, Charles M A, Bennett P H
Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation.
Arch Intern Med. 1991 Sep;151(9):1761-5.
The ability of an albumin-to-creatinine ratio, measured in a single untimed urine specimen, to indicate the likelihood of developing overt diabetic nephropathy was determined in 439 Pima Indians (134 men, 305 women) aged 25 years or older with non-insulin-dependent diabetes. During a mean follow-up period of 4.2 years, 59 (13%) of the subjects developed overt nephropathy, 47 (80%) of whom had albumin-to-creatinine ratios of 30 mg/g or greater at baseline. Subjects with albumin-to-creatinine ratios of 30 to 299 mg/g (a level of excretion often termed "microalbuminuria") had 9.2 times (95% confidence interval, 4.4 to 21.4) the incidence of overt nephropathy of those with ratios of less than 30 mg/g. Furthermore, the albumin-to-creatinine ratio remained a strong predictor of overt nephropathy even when controlled for age, sex, diabetes duration, mean blood pressure, and 2-hour postload plasma glucose concentration with a proportional-hazards function analysis. Thus, an albumin-to-creatinine ratio measured in a single untimed urine specimen is an effective means of identifying diabetic subjects who are at risk of developing overt nephropathy that could replace the more traditional timed urine collections.
在439名年龄在25岁及以上的非胰岛素依赖型糖尿病皮马印第安人(134名男性,305名女性)中,测定了单次随机尿样中白蛋白与肌酐比值用于指示发生显性糖尿病肾病可能性的能力。在平均4.2年的随访期内,59名(13%)受试者发生了显性肾病,其中47名(80%)在基线时白蛋白与肌酐比值为30mg/g或更高。白蛋白与肌酐比值为30至299mg/g(这一排泄水平常被称为“微量白蛋白尿”)的受试者发生显性肾病的几率是比值低于30mg/g者的9.2倍(95%置信区间为4.4至21.4)。此外,即使在通过比例风险函数分析对年龄、性别、糖尿病病程、平均血压和负荷后2小时血浆葡萄糖浓度进行控制后,白蛋白与肌酐比值仍是显性肾病的有力预测指标。因此,单次随机尿样中测得的白蛋白与肌酐比值是识别有发生显性肾病风险的糖尿病患者的有效方法,可取代更传统的定时尿样采集。